Document Detail


Is Parkinson's disease an autoimmune disorder of endogenous vasoactive neuropeptides?
MedLine Citation:
PMID:  17562359     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Parkinson's disease (PD) is a motor disease including disorders of mobility, fine tremor, rigidity and posture caused by a relentless deterioration of dopaminergic cells in the substantia nigra (SN). Disorders of affect and a range of other symptoms including fatigue, cognitive dysfunction and mental confusion, sleep disorder and addictions are also seen as other CNS sites are also affected. Idiopathic and genetic causes together with inflammatory and degenerative disorders of ageing have been postulated as contributing to PD. Autoimmunity affecting certain vasoactive neuropeptides (VNs) has been postulated as contributing to certain fatigue-related conditions in humans and may be consistent with compromise of receptors associated with VNs and including receptors for vasoactive intestinal polypeptide (VIP) and pituitary adenylate cyclase-activating polypeptide (PACAP). Pro-inflammatory responses are seen in PD patients consistent with apoptotic neurodegeneration. Involvement of the Th1 directed cytokine interferon-gamma has been demonstrated and Th2 directed cytokines such as IL-10 protect against inflammation-mediated degeneration of dopaminergic neurons in the SN. Nitric-oxide dysregulation is also postulated in PD by fostering dopamine depletion via nitric-oxide synthase (iNOS). Both PACAP and VIP have neuroprotective effects in PD models by inhibiting the production of inflammatory mediators. PACAP specifically protects against the neurotoxicity induced by rotenone as well as protecting against oxidative stress-induced apoptosis. These findings suggest that a defect in VN function may act adversely on SN cells and hence contribute to a clinical presentation consistent with PD. The conclusion drawn from these findings is that PD may be an autoimmune disorder of VNs, specifically PACAP and VIP. Possibly unusual or anatomically specific receptors for these VNs may be involved. If proven, this hypothesis would have significant implications for immunological and pharmacological treatment and prevention of PD.
Authors:
Donald R Staines
Related Documents :
20683679 - Inflammatory cytokine induced regulation of superoxide dismutase 3 expression by human ...
10818449 - Lysophosphatidic acid induction of neuronal apoptosis and necrosis.
18219389 - Erythropoietin deficiency decreases vascular stability in mice.
9207249 - Processing of alzheimer's amyloid precursor protein during h2o2-induced apoptosis in hu...
12387699 - Therapeutic developments in the treatment of amyotrophic lateral sclerosis.
18550289 - Methylprednisolone treatment delays remote cell death after focal brain lesion.
16596269 - Caspase-1 as a radio- and chemo-sensitiser in vitro and in vivo.
2055839 - Initial recruitment of neutrophils to alveolar structures in acute lung injury.
17914449 - Further exploring the brain-skin connection: stress worsens dermatitis via substance p-...
Publication Detail:
Type:  Journal Article     Date:  2007-06-11
Journal Detail:
Title:  Medical hypotheses     Volume:  69     ISSN:  0306-9877     ISO Abbreviation:  Med. Hypotheses     Publication Date:  2007  
Date Detail:
Created Date:  2007-10-30     Completed Date:  2008-01-03     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  7505668     Medline TA:  Med Hypotheses     Country:  Scotland    
Other Details:
Languages:  eng     Pagination:  1208-11     Citation Subset:  IM    
Affiliation:
Gold Coast Population Health Unit, 10-12 Young Street, Southport 4215, Qld., Australia. don_staines@health.qld.gov.au
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adenosine Triphosphate / metabolism
Animals
Apoptosis
Autoimmune Diseases / immunology*
Autoimmunity
Cyclic AMP / metabolism
Humans
Inflammation
Mice
Models, Theoretical
Neuropeptides / chemistry*
Neurotoxins
Parkinson Disease / immunology*,  prevention & control
Rotenone / pharmacology
Treatment Outcome
Chemical
Reg. No./Substance:
0/Neuropeptides; 0/Neurotoxins; 56-65-5/Adenosine Triphosphate; 60-92-4/Cyclic AMP; 83-79-4/Rotenone

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Dysfunction of AQP7 in the periadventitial fat: A novel trigger of atherosclerosis.
Next Document:  A computational docking study for prediction of binding mode of diospyrin and derivatives: Inhibitor...